Your browser doesn't support javascript.
loading
What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?
Lewis, Matthieu; Copland, Mhairi; Soverini, Simona; Sadovnik, Irina; Bedel, Aurélie; Prost, Stéphane; Italiano, Antoine; Mahon, François-Xavier.
Afiliación
  • Lewis M; Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, ACTION, INSERM U1218, University of Bordeaux, Bordeaux, Gironde, France.
  • Copland M; Institute of Cancer Sciences, University of Glasgow, Glasgow, Glasgow City Counsil, UK.
  • Soverini S; Department of Experimental, Diagnostic and Specialty Medicine, Haematology/Oncology "L. and A. Seràgnoli", University of Bologna, Bologna, Emilia-Romagna, Italy.
  • Sadovnik I; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Vienna, Austria.
  • Bedel A; Biothérapie de Maladies Génétiques et Cancer, INSERM U1035, Université de Bordeaux, Bordeaux, Gironde, France.
  • Prost S; CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), F-92265, Fontenay-aux-Roses, Île de France, France.
  • Italiano A; Department of Medical Oncology, Bergonié Institute, Bordeaux, Gironde, France.
  • Mahon FX; Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, ACTION, INSERM U1218, University of Bordeaux, Bordeaux, Gironde, France.
Hematol Oncol ; 35(4): 420-423, 2017 Dec.
Article en En | MEDLINE | ID: mdl-27435333
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hematol Oncol Año: 2017 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hematol Oncol Año: 2017 Tipo del documento: Article País de afiliación: Francia